Product References
SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape.
Science signaling
Wang Z,Pan B,Qiu J,Zhang X,Ke X,Shen S,Wu X,Yao Y,Tang N
Tue Mar 14 00:00:00 UTC 2023
SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape.
Science signaling
Wang Z,Pan B,Qiu J,Zhang X,Ke X,Shen S,Wu X,Yao Y,Tang N
Tue Mar 14 00:00:00 UTC 2023
PD-L1 upregulation promotes drug-induced pulmonary fibrosis by inhibiting vimentin degradation.
Pharmacological research
Li Q,Deng MS,Wang RT,Luo H,Luo YY,Zhang DD,Chen KJ,Cao XF,Yang GM,Zhao TM,Xu B,Xu CX,Wang JM
Sun Jan 01 00:00:00 UTC 2023
PD-L1 upregulation promotes drug-induced pulmonary fibrosis by inhibiting vimentin degradation.
Pharmacological research
Li Q,Deng MS,Wang RT,Luo H,Luo YY,Zhang DD,Chen KJ,Cao XF,Yang GM,Zhao TM,Xu B,Xu CX,Wang JM
Sun Jan 01 00:00:00 UTC 2023
PD-L1 upregulation promotes drug-induced pulmonary fibrosis by inhibiting vimentin degradation.
Pharmacological research
Li Q,Deng MS,Wang RT,Luo H,Luo YY,Zhang DD,Chen KJ,Cao XF,Yang GM,Zhao TM,Xu B,Xu CX,Wang JM
Sun Jan 01 00:00:00 UTC 2023
PD-L1 upregulation promotes drug-induced pulmonary fibrosis by inhibiting vimentin degradation.
Pharmacological research
Li Q,Deng MS,Wang RT,Luo H,Luo YY,Zhang DD,Chen KJ,Cao XF,Yang GM,Zhao TM,Xu B,Xu CX,Wang JM
Sun Jan 01 00:00:00 UTC 2023
Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression.
The Journal of nutritional biochemistry
Zhang Q,Cao W,Yang C,Hong L,Geng S,Han H,Zhong C
Wed Feb 01 00:00:00 UTC 2023
Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression.
The Journal of nutritional biochemistry
Zhang Q,Cao W,Yang C,Hong L,Geng S,Han H,Zhong C
Wed Feb 01 00:00:00 UTC 2023
Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression.
The Journal of nutritional biochemistry
Zhang Q,Cao W,Yang C,Hong L,Geng S,Han H,Zhong C
Wed Feb 01 00:00:00 UTC 2023
Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression.
The Journal of nutritional biochemistry
Zhang Q,Cao W,Yang C,Hong L,Geng S,Han H,Zhong C
Wed Feb 01 00:00:00 UTC 2023
Comprehensive Analyses Reveal Effects on Tumor Immune Infiltration and Immunotherapy Response of APOBEC Mutagenesis and Its Molecular Mechanisms in Esophageal Squamous Cell Carcinoma.
International journal of biological sciences
Yang J,Xiang T,Zhu S,Lao Y,Wang Y,Liu T,Li K,Ma Y,Zhong C,Zhang S,Tan W,Lin D,Wu C
Wed May 24 00:00:00 UTC 2023
FAM72A promotes glioma progression by regulating mitophagy through the Pink1/Parkin signaling pathway.
Journal of Cancer
Zeng Y,Xiong C,Tang N,Wang S,Xiong Z,Liang T,Wang Q,Li M,Li J
Tue Sep 17 00:00:00 UTC 2024
FAM72A promotes glioma progression by regulating mitophagy through the Pink1/Parkin signaling pathway.
Journal of Cancer
Zeng Y,Xiong C,Tang N,Wang S,Xiong Z,Liang T,Wang Q,Li M,Li J
Tue Sep 17 00:00:00 UTC 2024
Involvement of ZDHHC9 in lung adenocarcinoma: regulation of PD-L1 stability via palmitoylation.
In vitro cellular & developmental biology. Animal
Li Z,Jiang D,Liu F,Li Y
Wed Mar 01 00:00:00 UTC 2023
Exploring the relationship between abnormally high expression of NUP205 and the clinicopathological characteristics, immune microenvironment, and prognostic value of lower-grade glioma.
Frontiers in oncology
Liang W,Hu C,Zhu Q,Cheng X,Gao S,Liu Z,Wang H,Li P,Gao Y,Qian R
Thu Jun 08 00:00:00 UTC 2023
Targeting the mitochondrial calcium uniporter inhibits cancer progression and alleviates cisplatin resistance in esophageal squamous cell carcinoma.
International journal of oncology
Miao Y,Wang X,Lai Y,Huang Y,Yin H,Meng X,Liu H,Hou R,Lin W,Zhang X,Zhang X,Chai BC,Zhang F,Guo L,Yang S
Sat Jul 01 00:00:00 UTC 2023
Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer.
Cell death and differentiation
Yang H,Zhang X,Lao M,Sun K,He L,Xu J,Duan Y,Chen Y,Ying H,Li M,Guo C,Lu Q,Wang S,Su W,Liang T,Bai X
Wed Feb 01 00:00:00 UTC 2023
Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer.
Cell death and differentiation
Yang H,Zhang X,Lao M,Sun K,He L,Xu J,Duan Y,Chen Y,Ying H,Li M,Guo C,Lu Q,Wang S,Su W,Liang T,Bai X
Wed Feb 01 00:00:00 UTC 2023
Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer.
Cell death and differentiation
Yang H,Zhang X,Lao M,Sun K,He L,Xu J,Duan Y,Chen Y,Ying H,Li M,Guo C,Lu Q,Wang S,Su W,Liang T,Bai X
Wed Feb 01 00:00:00 UTC 2023
Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer.
Cell death and differentiation
Yang H,Zhang X,Lao M,Sun K,He L,Xu J,Duan Y,Chen Y,Ying H,Li M,Guo C,Lu Q,Wang S,Su W,Liang T,Bai X
Wed Feb 01 00:00:00 UTC 2023
Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer.
Cell death and differentiation
Yang H,Zhang X,Lao M,Sun K,He L,Xu J,Duan Y,Chen Y,Ying H,Li M,Guo C,Lu Q,Wang S,Su W,Liang T,Bai X
Wed Feb 01 00:00:00 UTC 2023
Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer.
Cell death and differentiation
Yang H,Zhang X,Lao M,Sun K,He L,Xu J,Duan Y,Chen Y,Ying H,Li M,Guo C,Lu Q,Wang S,Su W,Liang T,Bai X
Wed Feb 01 00:00:00 UTC 2023
TFAP2A promotes cervical cancer via a positive feedback pathway with PD‑L1.
Oncology reports
Yang J,Gao Y,Yao S,Wan S,Cai H
Thu Jun 01 00:00:00 UTC 2023
RUNX1/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: A single-cell sequencing analysis.
Frontiers in immunology
Zhang H,Cao H,Luo H,Zhang N,Wang Z,Dai Z,Wu W,Liu G,Xie Z,Cheng Q,Cheng Y
Tue Feb 14 00:00:00 UTC 2023
Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma.
EBioMedicine
Wen T,Sun G,Jiang W,He X,Shi Y,Ma F,Liu P
Sun Jan 01 00:00:00 UTC 2023
Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma.
EBioMedicine
Wen T,Sun G,Jiang W,He X,Shi Y,Ma F,Liu P
Sun Jan 01 00:00:00 UTC 2023
Warming Menstruation and Analgesic Soup Inhibits PD-1/PD-L1 Pathway in Rats with Endometriosis.
Alternative therapies in health and medicine
Feng D,Wang X,Huang Y,Chen X,Xu R,Qu Z,Chou D
Mon May 01 00:00:00 UTC 2023
PYCR1 promotes the malignant progression of lung cancer through the JAK-STAT3 signaling pathway via PRODH-dependent glutamine synthesize.
Translational oncology
Zhang L,Zhao X,Wang E,Yang Y,Hu L,Xu H,Zhang B
Thu Jun 01 00:00:00 UTC 2023
Inhibition of FGFR3 upregulates MHC-I and PD-L1 via TLR3/NF-kB pathway in muscle-invasive bladder cancer.
Cancer medicine
Wu W,Chen L,Jia G,Tang Q,Han B,Xia S,Jiang Q,Liu H
Sat Jul 01 00:00:00 UTC 2023
EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Pan Y,Shu G,Fu L,Huang K,Zhou X,Gui C,Liu H,Jin X,Chen M,Li P,Cen J,Feng Z,Lu J,Chen Z,Li J,Xu Q,Wang Y,Liang H,Wang Z,Deng Q,Chen W,Luo J,Yang J,Zhang J,Wei J
Sat Apr 01 00:00:00 UTC 2023
EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Pan Y,Shu G,Fu L,Huang K,Zhou X,Gui C,Liu H,Jin X,Chen M,Li P,Cen J,Feng Z,Lu J,Chen Z,Li J,Xu Q,Wang Y,Liang H,Wang Z,Deng Q,Chen W,Luo J,Yang J,Zhang J,Wei J
Sat Apr 01 00:00:00 UTC 2023
EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Pan Y,Shu G,Fu L,Huang K,Zhou X,Gui C,Liu H,Jin X,Chen M,Li P,Cen J,Feng Z,Lu J,Chen Z,Li J,Xu Q,Wang Y,Liang H,Wang Z,Deng Q,Chen W,Luo J,Yang J,Zhang J,Wei J
Sat Apr 01 00:00:00 UTC 2023
EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Pan Y,Shu G,Fu L,Huang K,Zhou X,Gui C,Liu H,Jin X,Chen M,Li P,Cen J,Feng Z,Lu J,Chen Z,Li J,Xu Q,Wang Y,Liang H,Wang Z,Deng Q,Chen W,Luo J,Yang J,Zhang J,Wei J
Sat Apr 01 00:00:00 UTC 2023
PPARγ agonist pioglitazone enhances colorectal cancer immunotherapy by inducing PD-L1 autophagic degradation.
European journal of pharmacology
Jia X,Qian J,Chen H,Liu Q,Hussain S,Jin J,Shi J,Hou Y
Wed Jul 05 00:00:00 UTC 2023
CJ: A Novel Potent Platinum(IV) Prodrug Enhances Chemo-Immunotherapy by Facilitating PD-L1 Degradation in the Cytoplasm and Cytomembrane.
Journal of medicinal chemistry
Fan R,Deng A,Qi B,Zhang S,Sang R,Luo L,Gou J,Liu Y,Lin R,Zhao M,Liu Y,Yang L,Cheng M,Wei G
Thu Jan 12 00:00:00 UTC 2023
CJ: A Novel Potent Platinum(IV) Prodrug Enhances Chemo-Immunotherapy by Facilitating PD-L1 Degradation in the Cytoplasm and Cytomembrane.
Journal of medicinal chemistry
Fan R,Deng A,Qi B,Zhang S,Sang R,Luo L,Gou J,Liu Y,Lin R,Zhao M,Liu Y,Yang L,Cheng M,Wei G
Thu Jan 12 00:00:00 UTC 2023
Dose-Dependent Effects in Plasma Oncotherapy: Critical In Vivo Immune Responses Missed by In Vitro Studies.
Biomolecules
He Y,Gong F,Jin T,Liu Q,Fang H,Chen Y,Wang G,Chu PK,Wu Z,Ostrikov KK
Fri Apr 21 00:00:00 UTC 2023
Dose-Dependent Effects in Plasma Oncotherapy: Critical In Vivo Immune Responses Missed by In Vitro Studies.
Biomolecules
He Y,Gong F,Jin T,Liu Q,Fang H,Chen Y,Wang G,Chu PK,Wu Z,Ostrikov KK
Fri Apr 21 00:00:00 UTC 2023
Dose-Dependent Effects in Plasma Oncotherapy: Critical In Vivo Immune Responses Missed by In Vitro Studies.
Biomolecules
He Y,Gong F,Jin T,Liu Q,Fang H,Chen Y,Wang G,Chu PK,Wu Z,Ostrikov KK
Fri Apr 21 00:00:00 UTC 2023
PPARγ inhibited tumor immune escape by inducing PD-L1 autophagic degradation.
Cancer science
Gou Q,Che S,Chen M,Chen H,Shi J,Hou Y
Sat Jul 01 00:00:00 UTC 2023
PPARγ inhibited tumor immune escape by inducing PD-L1 autophagic degradation.
Cancer science
Gou Q,Che S,Chen M,Chen H,Shi J,Hou Y
Sat Jul 01 00:00:00 UTC 2023
PPARγ inhibited tumor immune escape by inducing PD-L1 autophagic degradation.
Cancer science
Gou Q,Che S,Chen M,Chen H,Shi J,Hou Y
Sat Jul 01 00:00:00 UTC 2023
TREM2 as an independent predictor of poor prognosis promotes the migration via the PI3K/AKT axis in prostate cancer.
American journal of translational research
Gao HT,Yang Z,Sun H,Zhang Y,Wang Z,Liu WY,Wen HZ,Qu CB,Wang XL
Wed Mar 15 00:00:00 UTC 2023
GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer.
bioRxiv : the preprint server for biology
Huntington KE,Louie AD,Srinivasan PR,Schorl C,Lu S,Silverberg D,Newhouse D,Wu Z,Zhou L,Borden BA,Giles FJ,Dooner M,Carneiro BA,El-Deiry WS
Tue Feb 07 00:00:00 UTC 2023
Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer.
Cancer immunology, immunotherapy : CII
Yamaki H,Kono M,Wakisaka R,Komatsuda H,Kumai T,Hayashi R,Sato R,Nagato T,Ohkuri T,Kosaka A,Ohara K,Kishibe K,Takahara M,Hayashi T,Kobayashi H,Katada A
Tue Aug 01 00:00:00 UTC 2023
Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria.
Cell research
Xie XQ,Yang Y,Wang Q,Liu HF,Fang XY,Li CL,Jiang YZ,Wang S,Zhao HY,Miao JY,Ding SS,Liu XD,Yao XH,Yang WT,Jiang J,Shao ZM,Jin G,Bian XW
Wed Mar 01 00:00:00 UTC 2023
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer.
Immunotherapy
Li E,Xu J,Chen Q,Zhang X,Xu X,Liang T
Wed Feb 01 00:00:00 UTC 2023
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer.
Immunotherapy
Li E,Xu J,Chen Q,Zhang X,Xu X,Liang T
Wed Feb 01 00:00:00 UTC 2023
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer.
Immunotherapy
Li E,Xu J,Chen Q,Zhang X,Xu X,Liang T
Wed Feb 01 00:00:00 UTC 2023
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer.
Immunotherapy
Li E,Xu J,Chen Q,Zhang X,Xu X,Liang T
Wed Feb 01 00:00:00 UTC 2023
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer.
Immunotherapy
Li E,Xu J,Chen Q,Zhang X,Xu X,Liang T
Wed Feb 01 00:00:00 UTC 2023
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer.
Immunotherapy
Li E,Xu J,Chen Q,Zhang X,Xu X,Liang T
Wed Feb 01 00:00:00 UTC 2023
Supramolecular Exosome Array for Efficient Capture and In Situ Detection of Protein Biomarkers.
Analytical chemistry
Feng X,Iliuk A,Zhang X,Jia S,Shen A,Zhang W,Hu L,Tao WA
Tue Feb 07 00:00:00 UTC 2023
A novel immune score model predicting the prognosis and immunotherapy response of breast cancer.
Scientific reports
Lv W,He X,Wang Y,Zhao C,Dong M,Wu Y,Zhang Q
Wed Apr 19 00:00:00 UTC 2023
A Novel Tri-Functional Liposome Re-Educates "Cold Tumor" and Abrogates Tumor Growth by Synergizing Autophagy Inhibition and PD-L1 Blockade.
Advanced healthcare materials
Zhou F,Li X,Xue X,Li S,Fan G,Cai Y,Chang Z,Qu J,Liu R
Sat Apr 01 00:00:00 UTC 2023
S-allylmercaptocysteine promotes anti-tumor immunity by suppressing PD-L1 expression.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Zhao J,Sun Y,Gao P,Zhao Z,Wei G
Mon May 01 00:00:00 UTC 2023
S-allylmercaptocysteine promotes anti-tumor immunity by suppressing PD-L1 expression.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Zhao J,Sun Y,Gao P,Zhao Z,Wei G
Mon May 01 00:00:00 UTC 2023
Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma.
Journal of personalized medicine
Girolami I,Marletta S,Fiorentino V,Battocchio S,Cerbelli B,Fiamengo B,Gerosa C,Gianatti A,Morelli L,Riva G,Zagami MG,Fusco N,Munari E,L'Imperio V,Pagni F,Morbini P,Martini M,Eccher A
Sat Feb 18 00:00:00 UTC 2023
B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma.
Journal of experimental & clinical cancer research : CR
Cui Y,Li J,Zhang P,Yin D,Wang Z,Dai J,Wang W,Zhang E,Guo R
Mon Jun 12 00:00:00 UTC 2023
B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma.
Journal of experimental & clinical cancer research : CR
Cui Y,Li J,Zhang P,Yin D,Wang Z,Dai J,Wang W,Zhang E,Guo R
Mon Jun 12 00:00:00 UTC 2023
B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma.
Journal of experimental & clinical cancer research : CR
Cui Y,Li J,Zhang P,Yin D,Wang Z,Dai J,Wang W,Zhang E,Guo R
Mon Jun 12 00:00:00 UTC 2023
B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma.
Journal of experimental & clinical cancer research : CR
Cui Y,Li J,Zhang P,Yin D,Wang Z,Dai J,Wang W,Zhang E,Guo R
Mon Jun 12 00:00:00 UTC 2023
Exosomes derived from MDR cells induce cetuximab resistance in CRC via PI3K/AKT signaling‑mediated Sox2 and PD‑L1 expression.
Experimental and therapeutic medicine
Wei Z,Wang Z,Chai Q,Li Z,Zhang M,Zhang Y,Zhang L,Tang Q,Zhu H,Sui H
Wed Feb 01 00:00:00 UTC 2023
Exosomes derived from MDR cells induce cetuximab resistance in CRC via PI3K/AKT signaling‑mediated Sox2 and PD‑L1 expression.
Experimental and therapeutic medicine
Wei Z,Wang Z,Chai Q,Li Z,Zhang M,Zhang Y,Zhang L,Tang Q,Zhu H,Sui H
Wed Feb 01 00:00:00 UTC 2023
Crosstalk between 5-methylcytosine and N6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma.
Molecular cancer
Tian Y,Xiao H,Yang Y,Zhang P,Yuan J,Zhang W,Chen L,Fan Y,Zhang J,Cheng H,Deng T,Yang L,Wang W,Chen G,Wang P,Gong P,Niu X,Zhang X
Tue Jan 10 00:00:00 UTC 2023
HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway.
Journal of experimental & clinical cancer research : CR
Liu Y,Xu Q,Deng F,Zheng Z,Luo J,Wang P,Zhou J,Lu X,Zhang L,Chen Z,Zhang Q,Chen Q,Zuo D
Wed Feb 01 00:00:00 UTC 2023
The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic cancer via the CARD9-BCL10-MALT1 / NF-κB pathway.
Clinical immunology (Orlando, Fla.)
Li Q,He J,Li S,Tian C,Yang J,Yuan H,Lu Y,Fagone P,Nicoletti F,Xiang M
Wed Mar 01 00:00:00 UTC 2023
Engineering a facile and versatile nanoplatform to facilitate the delivery of multiple agents for targeted breast cancer chemo-immunotherapy.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Bahreyni A,Mohamud Y,Zhang J,Luo H
Sat Jul 01 00:00:00 UTC 2023
Comprehensive pan-cancer analysis identifies centromere-associated protein E as a novel prognostic and immunological biomarker in human tumors.
Biochimica et biophysica acta. General subjects
Yuan Y,Deng X,Wang S,Han S
Thu Jun 01 00:00:00 UTC 2023
The deubiquitinase OTUD1 noncanonically suppresses Akt activation through its N-terminal intrinsically disordered region.
Cell reports
Fan G,Wang F,Chen Y,Zheng Q,Xiong J,Lv Q,Wu K,Xiong J,Wei L,Li D,Zhang J,Zhang W,Li F
Tue Jan 31 00:00:00 UTC 2023
Targeting of Annexin A1 in Tumor-associated Macrophages as a therapeutic strategy for hepatocellular carcinoma.
Biochemical pharmacology
Song Z,Wang X,Liu X,Luo Y,Qiu J,Yin A,Liu Y,Yi H,Xiao Z,Li A
Sat Jul 01 00:00:00 UTC 2023
Identification of Hypoxia-Associated Signature in Colon Cancer to Assess Tumor Immune Microenvironment and Predict Prognosis Based on 14 Hypoxia-Associated Genes.
International journal of general medicine
Chen P,Li Z,Liang Y,Wei M,Jiang H,Chen S,Zhao Z
Sat Jul 01 00:00:00 UTC 2023
Retinoic acid-loaded PLGA nanocarriers targeting cell cholesterol potentialize the antitumour effect of PD-L1 antibody by preventing epithelial-mesenchymal transition mediated by M2-TAM in colorectal cancer.
Translational oncology
Júnior RFA,Lira GA,Schomann T,Cavalcante RS,Vilar NF,de Paula RCM,Gomes RF,Chung CK,Jorquera-Cordero C,Vepris O,Chan AB,Cruz LJ
Mon May 01 00:00:00 UTC 2023
Sinonasal NUT carcinoma: A retrospective case series from a single institution.
Frontiers in surgery
Wang L,Zhu Z,Wang W,Zha Y,Wang X,Surita A,Liu Y,Lv W
Tue Mar 21 00:00:00 UTC 2023
An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma.
Clinical and experimental medicine
Yang L,Zhao Q,Chen T,Liu W,Qiu X,Chen J,Huang S,Huang R,Dong L
Wed Nov 01 00:00:00 UTC 2023
Formin protein DIAPH1 positively regulates PD-L1 expression and predicts the therapeutic response to anti-PD-1/PD-L1 immunotherapy.
Clinical immunology (Orlando, Fla.)
Mei J,Cai Y,Wang H,Xu R,Zhou J,Lu J,Yang X,Pan J,Liu C,Xu J,Zhu Y
Sun Jan 01 00:00:00 UTC 2023
Pan-cancer analysis reveals potential of FAM110A as a prognostic and immunological biomarker in human cancer.
Frontiers in immunology
Zhong H,Shi Q,Wen Q,Chen J,Li X,Ruan R,Zeng S,Dai X,Xiong J,Li L,Lei W,Deng J
Tue Mar 21 00:00:00 UTC 2023
SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers.
iScience
Mei J,Fu Z,Cai Y,Song C,Zhou J,Zhu Y,Mao W,Xu J,Yin Y
Fri Feb 17 00:00:00 UTC 2023
The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma.
Journal of clinical medicine
Zhang Z,Xiong Q,Xu Y,Cai X,Zhang L,Zhu Q
Thu Feb 09 00:00:00 UTC 2023
An inflammation-associated ferroptosis signature optimizes the diagnosis, prognosis evaluation and immunotherapy options in hepatocellular carcinoma.
Journal of cellular and molecular medicine
Ruan WY,Zhang L,Lei S,Zeng ZR,Yang YS,Cao WP,Hao QY,Lu M,Tian XB,Peng PL
Sat Jul 01 00:00:00 UTC 2023
Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis.
Cellular & molecular immunology
Lau P,Zhang G,Zhao S,Liang L,Zhang H,Zhou G,Hung MC,Chen X,Liu H
Sat Oct 01 00:00:00 UTC 2022
Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis.
Cellular & molecular immunology
Lau P,Zhang G,Zhao S,Liang L,Zhang H,Zhou G,Hung MC,Chen X,Liu H
Sat Oct 01 00:00:00 UTC 2022
m5C regulator-mediated modification patterns and tumor microenvironment infiltration characterization in colorectal cancer: One step closer to precision medicine.
Frontiers in immunology
Chen B,Xi Y,Zhao J,Hong Y,Tian S,Zhai X,Chen Q,Ren X,Fan L,Xie X,Jiang C
Tue Dec 20 00:00:00 UTC 2022
Pan-Cancer Analysis of the Immunological Role of PDIA5: A Potential Target for Immunotherapy.
Frontiers in immunology
Chen Y,He J,Chen R,Wang Z,Dai Z,Liang X,Wu W,Luo P,Zhang J,Peng Y,Zhang N,Liu Z,Zhang L,Zhang H,Cheng Q
Fri Aug 26 00:00:00 UTC 2022
PD-L1/PD-L1 signalling promotes colorectal cancer cell migration ability through RAS/MEK/ERK.
Clinical and experimental pharmacology & physiology
Cao Y,Liang W,Fang L,Liu MK,Zuo J,Peng YL,Shan JJ,Sun RX,Zhao J,Wang J
Thu Dec 01 00:00:00 UTC 2022
PD-L1/PD-L1 signalling promotes colorectal cancer cell migration ability through RAS/MEK/ERK.
Clinical and experimental pharmacology & physiology
Cao Y,Liang W,Fang L,Liu MK,Zuo J,Peng YL,Shan JJ,Sun RX,Zhao J,Wang J
Thu Dec 01 00:00:00 UTC 2022
CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy.
Oncoimmunology
Li X,Lu M,Yuan M,Ye J,Zhang W,Xu L,Wu X,Hui B,Yang Y,Wei B,Guo C,Wei M,Dong J,Wu X,Gu Y
Tue Sep 13 00:00:00 UTC 2022
CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy.
Oncoimmunology
Li X,Lu M,Yuan M,Ye J,Zhang W,Xu L,Wu X,Hui B,Yang Y,Wei B,Guo C,Wei M,Dong J,Wu X,Gu Y
Tue Sep 13 00:00:00 UTC 2022
Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma.
Theranostics
Zhang N,Zhang H,Wu W,Zhou R,Li S,Wang Z,Dai Z,Zhang L,Liu F,Liu Z,Zhang J,Luo P,Liu Z,Cheng Q
Tue Aug 16 00:00:00 UTC 2022
Self-Assembly of Podophyllotoxin-Loaded Lipid Bilayer Nanoparticles for Highly Effective Chemotherapy and Immunotherapy via Downregulation of Programmed Cell Death Ligand 1 Production.
ACS nano
Wang R,Zhao Y,Huang Z,Zhou Y,Wang W,Xuan Y,Zhen Y,Ju B,Guo S,Zhang S
Tue Mar 22 00:00:00 UTC 2022
Combined expression of the mutation and PD-L1 in early papillary thyroid carcinoma and its relationship with clinicopathological features and recurrence-a retrospective cohort study.
Gland surgery
Zhang M,Gu J,Wang W,Wang K,Zheng L,Feng J,Shang J
Thu Dec 01 00:00:00 UTC 2022
Overexpression of PD-L1 causes germ cells to slough from mouse seminiferous tubules via the PD-L1/PD-L1 interaction.
Journal of cellular and molecular medicine
Fang L,Feng R,Liang W,Liu FF,Bian GL,Yu C,Guo H,Cao Y,Liu M,Zuo J,Peng Y,Zhao J,Sun RX,Shan J,Wang J
Sun May 01 00:00:00 UTC 2022
eIF6 is potential diagnostic and prognostic biomarker that associated with 18F-FDG PET/CT features and immune signatures in esophageal carcinoma.
Journal of translational medicine
Gao Y,Yuan L,Zeng J,Li F,Li X,Tan F,Liu X,Wan H,Kui X,Liu X,Ke C,Pei Z
Wed Jul 06 00:00:00 UTC 2022
Identification of stromal microenvironment characteristics and key molecular mining in pancreatic cancer.
Discover oncology
Ji H,Zhang Q,Wang XX,Li J,Wang X,Pan W,Zhang Z,Ma B,Zhang HM
Thu Aug 25 00:00:00 UTC 2022
Suppression of PD-L1 release from small extracellular vesicles promotes systemic anti-tumor immunity by targeting ORAI1 calcium channels.
Journal of extracellular vesicles
Chen X,Li J,Zhang R,Zhang Y,Wang X,Leung EL,Ma L,Wong VKW,Liu L,Neher E,Yu H
Thu Dec 01 00:00:00 UTC 2022
Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
Cell communication and signaling : CCS
Zhu P,Jin Z,Kang G,Jia Y,Liu D,Zhang Q,Guo F,Jia Y,Jiao Y,Li J,Sun H,Ma X
Mon Aug 15 00:00:00 UTC 2022
Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
Cell communication and signaling : CCS
Zhu P,Jin Z,Kang G,Jia Y,Liu D,Zhang Q,Guo F,Jia Y,Jiao Y,Li J,Sun H,Ma X
Mon Aug 15 00:00:00 UTC 2022
Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
Cell communication and signaling : CCS
Zhu P,Jin Z,Kang G,Jia Y,Liu D,Zhang Q,Guo F,Jia Y,Jiao Y,Li J,Sun H,Ma X
Mon Aug 15 00:00:00 UTC 2022
Quantification of promoting efficiency and reducing toxicity of Traditional Chinese Medicine: A case study of the combination of Tripterygium wilfordii hook. f. and Lysimachia christinae hance in the treatment of lung cancer.
Frontiers in pharmacology
Zhang X,Wang K,Dai H,Cai J,Liu Y,Yin C,Wu J,Li X,Wu G,Lu A,Liu Q,Guan D
Fri Sep 06 00:00:00 UTC 2024
The α5-nAChR/PD-L1 axis facilitates lung adenocarcinoma cell migration and invasion.
Human cell
Zhu P,Kang G,Jiao Y,Gui C,Fan H,Li X,Jia Y,Zhang L,Ma X
Fri Jul 01 00:00:00 UTC 2022
The α5-nAChR/PD-L1 axis facilitates lung adenocarcinoma cell migration and invasion.
Human cell
Zhu P,Kang G,Jiao Y,Gui C,Fan H,Li X,Jia Y,Zhang L,Ma X
Fri Jul 01 00:00:00 UTC 2022
Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma.
Frontiers in immunology
Zhu J,Huang Q,Liu S,Peng X,Xue J,Feng T,Huang W,Chen Z,Lai K,Ji Y,Wang M,Yuan R
Fri Apr 29 00:00:00 UTC 2022
RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer.
Journal of experimental & clinical cancer research : CR
Yang H,Xue M,Su P,Zhou Y,Li X,Li Z,Xia Y,Zhang C,Fu M,Zheng X,Luo G,Wei T,Wang X,Ding Y,Zhu J,Zhuang T
Thu Dec 29 00:00:00 UTC 2022
RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer.
Journal of experimental & clinical cancer research : CR
Yang H,Xue M,Su P,Zhou Y,Li X,Li Z,Xia Y,Zhang C,Fu M,Zheng X,Luo G,Wei T,Wang X,Ding Y,Zhu J,Zhuang T
Thu Dec 29 00:00:00 UTC 2022
Bacteria-mediated tumor immunotherapy via photothermally-programmed PD1 expression.
Nanoscale advances
Xu W,Ren D,Yu Z,Hou J,Huang F,Gan T,Ji P,Zhang C,Ma L,Hu Y
Tue Mar 15 00:00:00 UTC 2022
Anlotinib combined with the PD-L1 blockade exerts the potent anti-tumor immunity in renal cancer treatment.
Experimental cell research
Li J,Cao P,Chen Y,Wang J,Sun X,Chen R,Wang G,Hou J
Mon Aug 01 00:00:00 UTC 2022
Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model.
Bioengineered
Pan X,Yi M,Liu C,Jin Y,Liu B,Hu G,Yuan X
Tue Feb 01 00:00:00 UTC 2022
Mitochondria-Targeting Polymer Micelle of Dichloroacetate Induced Pyroptosis to Enhance Osteosarcoma Immunotherapy.
ACS nano
Jin J,Yuan P,Yu W,Lin J,Xu A,Xu X,Lou J,Yu T,Qian C,Liu B,Song J,Li L,Piao Y,Xie T,Shen Y,Tao H,Tang J
Tue Jul 26 00:00:00 UTC 2022
UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer.
Theranostics
Wu B,Song M,Dong Q,Xiang G,Li J,Ma X,Wei F
Mon Jul 18 00:00:00 UTC 2022
IL-7-Treated Periodontal Ligament Cells Regulate Local Immune Homeostasis by Modulating Treg/Th17 Cell Polarization.
Frontiers in medicine
Yu XY,Zhang ZQ,Huang JC,Lin JY,Cai XP,Liu CF
Tue Mar 15 00:00:00 UTC 2022
EphA2 Promotes the Development of Cervical Cancer through the CXCL11/PD-L1 Pathway.
Journal of oncology
Zhao X,Liu J,Jin D,Ren C,Yang L,Zhu Y,Huang C,Ding L,Wu Z,Shen K,Zhang Z,Chen H,Wang N
Sat Dec 10 00:00:00 UTC 2022
Enhanced Programmed Cell Death Protein 1/Programmed Cell Death Ligand 1 Expression Induced by Severe Influenza A Virus Infection Impairs Host's Antiviral Response.
Viral immunology
Ou H,Chen L,Wu H
Sat Oct 01 00:00:00 UTC 2022
Enhanced Programmed Cell Death Protein 1/Programmed Cell Death Ligand 1 Expression Induced by Severe Influenza A Virus Infection Impairs Host's Antiviral Response.
Viral immunology
Ou H,Chen L,Wu H
Sat Oct 01 00:00:00 UTC 2022
Programmed death ligand 1 and tumor-infiltrating CD8+ T lymphocytes are associated with the clinical features in meningioma.
BMC cancer
Zhang Y,Wang X,Shi M,Song Y,Yu J,Han S
Sat Nov 12 00:00:00 UTC 2022
Programmed death ligand 1 and tumor-infiltrating CD8+ T lymphocytes are associated with the clinical features in meningioma.
BMC cancer
Zhang Y,Wang X,Shi M,Song Y,Yu J,Han S
Sat Nov 12 00:00:00 UTC 2022
Dishevelled-Associated Activator of Morphogenesis 2 (DAAM2) Predicts the Immuno-Hot Phenotype in Pancreatic Adenocarcinoma.
Frontiers in molecular biosciences
Zhang Q,Pan J,Nie H,Wang H,An F,Zhan Q
Wed Mar 16 00:00:00 UTC 2022
Tripartite motif-containing 25 facilitates immunosuppression and inhibits apoptosis of glioma via activating NF-κB.
Experimental biology and medicine (Maywood, N.J.)
Ge MX,Shi YK,Liu D
Thu Sep 01 00:00:00 UTC 2022
INPP4B inhibits glioma cell proliferation and immune escape via inhibition of the PI3K/AKT signaling pathway.
Frontiers in oncology
Sun X,Chen Y,Tao X,Zhang W,Wang X,Wang X,Ruan Z,Chen Z
Sat Sep 24 00:00:00 UTC 2022
Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer.
Journal of oncology
Xu J,Yang X,Pan J,Fan H,Mei J,Hua D
Mon May 02 00:00:00 UTC 2022
Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer.
Journal of oncology
Xu J,Yang X,Pan J,Fan H,Mei J,Hua D
Mon May 02 00:00:00 UTC 2022
Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer.
Journal of oncology
Xu J,Yang X,Pan J,Fan H,Mei J,Hua D
Mon May 02 00:00:00 UTC 2022
Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer.
Journal of oncology
Xu J,Yang X,Pan J,Fan H,Mei J,Hua D
Mon May 02 00:00:00 UTC 2022
CMTM6: increased circulating level and up-regulated expression in labial salivary glands in patients with primary Sjogren's syndrome.
Clinical and experimental immunology
Qian S,Xu J,Zhao S,Yang P,Yang C
Fri Jan 28 00:00:00 UTC 2022
Matrix stiffness-dependent STEAP3 coordinated with PD-L2 identify tumor responding to sorafenib treatment in hepatocellular carcinoma.
Cancer cell international
Wang S,Chen L,Liu W
Thu Oct 13 00:00:00 UTC 2022
The miR-199a-5p/PD-L1 axis regulates cell proliferation, migration and invasion in follicular thyroid carcinoma.
BMC cancer
Lin J,Qiu Y,Zheng X,Dai Y,Xu T
Mon Jul 11 00:00:00 UTC 2022
The miR-199a-5p/PD-L1 axis regulates cell proliferation, migration and invasion in follicular thyroid carcinoma.
BMC cancer
Lin J,Qiu Y,Zheng X,Dai Y,Xu T
Mon Jul 11 00:00:00 UTC 2022
Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment.
Journal of translational medicine
Yang ZY,Jiang CW,Zhang WL,Sun G
Sat Jun 18 00:00:00 UTC 2022
miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma.
Molecular therapy oncolytics
Pathania AS,Prathipati P,Olwenyi OA,Chava S,Smith OV,Gupta SC,Chaturvedi NK,Byrareddy SN,Coulter DW,Challagundla KB
Thu Jun 16 00:00:00 UTC 2022
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.
Oncoimmunology
Lin J,Xu A,Jin J,Zhang M,Lou J,Qian C,Zhu J,Wang Y,Yang Z,Li X,Yu W,Liu B,Tao H
Mon Jan 31 00:00:00 UTC 2022
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.
Oncoimmunology
Lin J,Xu A,Jin J,Zhang M,Lou J,Qian C,Zhu J,Wang Y,Yang Z,Li X,Yu W,Liu B,Tao H
Mon Jan 31 00:00:00 UTC 2022
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.
Oncoimmunology
Lin J,Xu A,Jin J,Zhang M,Lou J,Qian C,Zhu J,Wang Y,Yang Z,Li X,Yu W,Liu B,Tao H
Mon Jan 31 00:00:00 UTC 2022
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.
Oncoimmunology
Lin J,Xu A,Jin J,Zhang M,Lou J,Qian C,Zhu J,Wang Y,Yang Z,Li X,Yu W,Liu B,Tao H
Mon Jan 31 00:00:00 UTC 2022
Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis.
Journal for immunotherapy of cancer
Tang T,Huang X,Zhang G,Lu M,Hong Z,Wang M,Huang J,Zhi X,Liang T
Tue Mar 01 00:00:00 UTC 2022
Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis.
Journal for immunotherapy of cancer
Tang T,Huang X,Zhang G,Lu M,Hong Z,Wang M,Huang J,Zhi X,Liang T
Tue Mar 01 00:00:00 UTC 2022
Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis.
Journal for immunotherapy of cancer
Tang T,Huang X,Zhang G,Lu M,Hong Z,Wang M,Huang J,Zhi X,Liang T
Tue Mar 01 00:00:00 UTC 2022
Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis.
Journal for immunotherapy of cancer
Tang T,Huang X,Zhang G,Lu M,Hong Z,Wang M,Huang J,Zhi X,Liang T
Tue Mar 01 00:00:00 UTC 2022
PD-L1 negatively regulates antifungal immunity by inhibiting neutrophil release from bone marrow.
Nature communications
Yu Y,Wang RR,Miao NJ,Tang JJ,Zhang YW,Lu XR,Yan PY,Wang J,Jia XM
Fri Nov 11 00:00:00 UTC 2022
A Dual-Reporter Platform for Screening Tumor-Targeted Extracellular Vesicles.
Pharmaceutics
Kanada M,Linenfelser L,Cox E,Gilad AA
Tue Feb 22 00:00:00 UTC 2022
Rapid Capturing and Chemiluminescent Sensing of Programmed Death Ligand-1 Expressing Extracellular Vesicles.
Biosensors
Khan A,Di K,Khan H,He N,Li Z
Thu Apr 28 00:00:00 UTC 2022
Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma.
Briefings in bioinformatics
Zhang H,Zhang N,Wu W,Zhou R,Li S,Wang Z,Dai Z,Zhang L,Liu Z,Zhang J,Luo P,Liu Z,Cheng Q
Sat Nov 19 00:00:00 UTC 2022
Downregulation of PD-L1 and HLA-I in non-small cell lung cancer with ALK fusion.
Thoracic cancer
Mu D,Guo J,Yu W,Zhang J,Ren X,Han Y
Fri Apr 01 00:00:00 UTC 2022
CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer.
Biochemical and biophysical research communications
Ren W,Ren J,Zhang N,Liu X,Deng Y,Jiang Y,Yan B,Xiao X,Yu H
Tue Jul 12 00:00:00 UTC 2022
CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer.
Biochemical and biophysical research communications
Ren W,Ren J,Zhang N,Liu X,Deng Y,Jiang Y,Yan B,Xiao X,Yu H
Tue Jul 12 00:00:00 UTC 2022
CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer.
Biochemical and biophysical research communications
Ren W,Ren J,Zhang N,Liu X,Deng Y,Jiang Y,Yan B,Xiao X,Yu H
Tue Jul 12 00:00:00 UTC 2022
CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer.
Biochemical and biophysical research communications
Ren W,Ren J,Zhang N,Liu X,Deng Y,Jiang Y,Yan B,Xiao X,Yu H
Tue Jul 12 00:00:00 UTC 2022
Expression of nucleus accumbens-1 in colon cancer negatively modulates antitumor immunity.
World journal of gastrointestinal oncology
Shen ZH,Luo WW,Ren XC,Wang XY,Yang JM
Thu Dec 15 00:00:00 UTC 2022
Thalidomide-based Pt(IV) prodrugs designed to exert synergistic effect of immunomodulation and chemotherapy.
Journal of inorganic biochemistry
Li Z,Ding XJ,Qiao X,Liu XM,Qiao X,Xie CZ,Liu RP,Xu JY
Fri Jul 01 00:00:00 UTC 2022
Cationic Nanoparticulate System for Codelivery of MicroRNA-424 and Podophyllotoxin as a Multimodal Anticancer Therapy.
Molecular pharmaceutics
Wang R,Xuan Y,Zhao Y,Wang W,Ma P,Ju B,Zhen Y,Zhang S
Mon Jul 04 00:00:00 UTC 2022
The immunomodulatory effect of microglia on ECM neuroinflammation via the PD-1/PD-L1 pathway.
CNS neuroscience & therapeutics
Shen Y,Li Y,Zhu Q,Wang J,Huang Y,Liang J,Wu X,Zhao Y
Sat Jan 01 00:00:00 UTC 2022
The immunomodulatory effect of microglia on ECM neuroinflammation via the PD-1/PD-L1 pathway.
CNS neuroscience & therapeutics
Shen Y,Li Y,Zhu Q,Wang J,Huang Y,Liang J,Wu X,Zhao Y
Sat Jan 01 00:00:00 UTC 2022
A Selective Small-Molecule c-Myc Degrader Potently Regresses Lethal c-Myc Overexpressing Tumors.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Xu Y,Yu Q,Wang P,Wu Z,Zhang L,Wu S,Li M,Wu B,Li H,Zhuang H,Zhang X,Huang Y,Gan X,Xu R
Tue Mar 01 00:00:00 UTC 2022
Anti-PD-L1 antibody alleviates pulmonary fibrosis by inducing autophagy via inhibition of the PI3K/Akt/mTOR pathway.
International immunopharmacology
Lu Y,Zhong W,Liu Y,Chen W,Zhang J,Zeng Z,Huang H,Qiao Y,Wan X,Meng X,Cai S,Dong H
Tue Mar 01 00:00:00 UTC 2022
Anti-PD-L1 antibody alleviates pulmonary fibrosis by inducing autophagy via inhibition of the PI3K/Akt/mTOR pathway.
International immunopharmacology
Lu Y,Zhong W,Liu Y,Chen W,Zhang J,Zeng Z,Huang H,Qiao Y,Wan X,Meng X,Cai S,Dong H
Tue Mar 01 00:00:00 UTC 2022
LINC00244 suppresses cell growth and metastasis in hepatocellular carcinoma by downregulating programmed cell death ligand 1.
Bioengineered
Sun Z,Xue C,Li J,Zhao H,Du Y,Du N
Tue Mar 01 00:00:00 UTC 2022
LINC00244 suppresses cell growth and metastasis in hepatocellular carcinoma by downregulating programmed cell death ligand 1.
Bioengineered
Sun Z,Xue C,Li J,Zhao H,Du Y,Du N
Tue Mar 01 00:00:00 UTC 2022
Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer.
JCI insight
Mao W,Cai Y,Chen D,Jiang G,Xu Y,Chen R,Wang F,Wang X,Zheng M,Zhao X,Mei J
Thu Sep 22 00:00:00 UTC 2022
Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer.
JCI insight
Mao W,Cai Y,Chen D,Jiang G,Xu Y,Chen R,Wang F,Wang X,Zheng M,Zhao X,Mei J
Thu Sep 22 00:00:00 UTC 2022
Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer.
JCI insight
Mao W,Cai Y,Chen D,Jiang G,Xu Y,Chen R,Wang F,Wang X,Zheng M,Zhao X,Mei J
Thu Sep 22 00:00:00 UTC 2022
Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer.
JCI insight
Mao W,Cai Y,Chen D,Jiang G,Xu Y,Chen R,Wang F,Wang X,Zheng M,Zhao X,Mei J
Thu Sep 22 00:00:00 UTC 2022
CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer.
Cancer science
Niu X,Wang W,Liang T,Li S,Yang C,Xu X,Li L,Liu S
Sat Jan 01 00:00:00 UTC 2022
An electrochemical biosensor for the assessment of tumor immunotherapy based on the detection of immune checkpoint protein programmed death ligand-1.
Biosensors & bioelectronics
Du X,Li Y,Zhang Z,Zhang C,Hu J,Wang X,Zhang R,Yang J,Zhou L,Zhang H,Liu M,Zhou J
Fri Jul 01 00:00:00 UTC 2022
Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing γδ T cells.
Nature communications
Du Y,Peng Q,Cheng D,Pan T,Sun W,Wang H,Ma X,He R,Zhang H,Cui Z,Feng X,Liu Z,Zhao T,Hu W,Shen L,Jiang W,Gao N,Martin BN,Zhang CJ,Zhang Z,Wang C
Tue Jan 11 00:00:00 UTC 2022
Advances in the drug management of basal cell carcinoma.
Expert opinion on pharmacotherapy
Ramelyte E,Restivo G,Mannino M,Levesque MP,Dummer R
Fri Apr 01 00:00:00 UTC 2022
Glioma-targeted multifunctional nanoparticles to co-deliver camptothecin and curcumin for enhanced chemo-immunotherapy.
Biomaterials science
Wang Z,Wang X,Yu H,Chen M
Wed Mar 02 00:00:00 UTC 2022
Design, Synthesis, and Biological Evaluation of Dual-Target COX-2/CYP51 Inhibitors for the Treatment of Fungal Infectious Diseases.
Journal of medicinal chemistry
Liu W,Liu Y,Fan H,Liu M,Han J,An Y,Dong Y,Sun B
Thu Sep 22 00:00:00 UTC 2022
Design, Synthesis, and Biological Evaluation of Dual-Target COX-2/CYP51 Inhibitors for the Treatment of Fungal Infectious Diseases.
Journal of medicinal chemistry
Liu W,Liu Y,Fan H,Liu M,Han J,An Y,Dong Y,Sun B
Thu Sep 22 00:00:00 UTC 2022
Fibroblast Common Serum Response Signature-Related Classification Affects the Tumour Microenvironment and Predicts Prognosis in Bladder Cancer.
Oxidative medicine and cellular longevity
Yang X,Zhou Y,Huang L,Lin S,Ye H,Shan Y
Tue Nov 08 00:00:00 UTC 2022
Single-cell transcriptome profiling of the immune space-time landscape reveals dendritic cell regulatory program in polymicrobial sepsis.
Theranostics
Yao RQ,Li ZX,Wang LX,Li YX,Zheng LY,Dong N,Wu Y,Xia ZF,Billiar TR,Ren C,Yao YM
Fri Jul 15 00:00:00 UTC 2022
STAT3/NF-κB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer.
British journal of pharmacology
Cavalcante RS,Ishikawa U,Silva ES,Silva-Júnior AA,Araújo AA,Cruz LJ,Chan AB,de Araújo Júnior RF
Tue Jun 01 00:00:00 UTC 2021
Nutritional supplements in combination with chemotherapy or targeted therapy reduces tumor progression in mice bearing triple-negative breast cancer.
The Journal of nutritional biochemistry
Guo CH,Hsia S,Chung CH,Lin YC,Shih MY,Chen PC,Peng CL,Henning SM,Hsu GW,Li Z
Fri Jan 01 00:00:00 UTC 2021
Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy.
Biochemical and biophysical research communications
Yuan J,Li J,Shang M,Fu Y,Wang T
Mon Jul 05 00:00:00 UTC 2021
Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.
Journal of experimental & clinical cancer research : CR
Li E,Huang X,Zhang G,Liang T
Fri Sep 03 00:00:00 UTC 2021
Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.
Journal of experimental & clinical cancer research : CR
Li E,Huang X,Zhang G,Liang T
Fri Sep 03 00:00:00 UTC 2021
The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
Annals of translational medicine
Tian Y,Sun X,Cheng G,Ji E,Yang S,Feng J,Zheng L
Fri Jan 01 00:00:00 UTC 2021
Cascade-Responsive Hierarchical Nanosystems for Multisite Specific Drug Exposure and Boosted Chemoimmunotherapy.
ACS applied materials & interfaces
Zhang J,Zhang Y,Zhao B,Lv M,Chen E,Zhao C,Jiang L,Qian H,Huang D,Zhong Y,Chen W
Wed Dec 15 00:00:00 UTC 2021
Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1.
Acta biochimica et biophysica Sinica
Yang Y,Wang C,Dai C,Liu X,Li W,Huang M,Zhao X,Ji D,Li J,Guo W
Thu Apr 15 00:00:00 UTC 2021
CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways.
Frontiers in oncology
Chen X,He H,Xiao Y,Hasim A,Yuan J,Ye M,Li X,Hao Y,Guo X
Wed Aug 14 00:00:00 UTC 2024
CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways.
Frontiers in oncology
Chen X,He H,Xiao Y,Hasim A,Yuan J,Ye M,Li X,Hao Y,Guo X
Wed Aug 14 00:00:00 UTC 2024
The PD-1/PD-L1 pathway in murine hair cycle transition: a potential anagen phase regulator.
Archives of dermatological research
Zhou L,Wen L,Sheng Y,Lu J,Hu R,Wang X,Lu Z,Yang Q
Mon Nov 01 00:00:00 UTC 2021
Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
Cell death & disease
Yin H,Pu N,Chen Q,Zhang J,Zhao G,Xu X,Wang D,Kuang T,Jin D,Lou W,Wu W
Sat Oct 30 00:00:00 UTC 2021
Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
Cell death & disease
Yin H,Pu N,Chen Q,Zhang J,Zhao G,Xu X,Wang D,Kuang T,Jin D,Lou W,Wu W
Sat Oct 30 00:00:00 UTC 2021
NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma.
Cancer letters
Lu F,Zhao Y,Pang Y,Ji M,Sun Y,Wang H,Zou J,Wang Y,Li G,Sun T,Li J,Ma D,Ye J,Ji C
Thu Jan 28 00:00:00 UTC 2021
NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma.
Cancer letters
Lu F,Zhao Y,Pang Y,Ji M,Sun Y,Wang H,Zou J,Wang Y,Li G,Sun T,Li J,Ma D,Ye J,Ji C
Thu Jan 28 00:00:00 UTC 2021
PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity.
Genome biology
Qu S,Jiao Z,Lu G,Yao B,Wang T,Rong W,Xu J,Fan T,Sun X,Yang R,Wang J,Yao Y,Xu G,Yan X,Wang T,Liang H,Zen K
Tue Apr 13 00:00:00 UTC 2021
The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma.
Frontiers in oncology
Huang J,Zhang L,Chen J,Wan D,Zhou L,Zheng S,Qiao Y
Wed Apr 27 00:00:00 UTC 2022
NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion.
Cell metabolism
Lv H,Lv G,Chen C,Zong Q,Jiang G,Ye D,Cui X,He Y,Xiang W,Han Q,Tang L,Yang W,Wang H
Tue Jan 05 00:00:00 UTC 2021
Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review.
The American Journal of dermatopathology
Lehmer L,Choi F,Kraus C,Shiu J,de Feraudy S,Elsensohn A
Sat May 01 00:00:00 UTC 2021
Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients.
Cancer cell international
Deng M,Li SH,Fu X,Yan XP,Chen J,Qiu YD,Guo RP
Mon Jul 12 00:00:00 UTC 2021
Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy.
Cancer cell international
Liu J,Liu Q,Zhang X,Cui M,Li T,Zhang Y,Liao Q
Fri Feb 26 00:00:00 UTC 2021
ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.
Nature communications
Wu Y,Zhang C,Liu X,He Z,Shan B,Zeng Q,Zhao Q,Zhu H,Liao H,Cen X,Xu X,Zhang M,Hou T,Wang Z,Yan H,Yang S,Sun Y,Chen Y,Wu R,Xie T,Chen W,Najafov A,Ying S,Xia H
Tue Apr 20 00:00:00 UTC 2021
Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.
The Prostate
Imamura R,Kitagawa S,Kubo T,Irie A,Kariu T,Yoneda M,Kamba T,Imamura T
Mon Feb 01 00:00:00 UTC 2021
Tumor cell membrane-based peptide delivery system targeting the tumor microenvironment for cancer immunotherapy and diagnosis.
Acta biomaterialia
Meng X,Wang J,Zhou J,Tian Q,Qie B,Zhou G,Duan W,Zhu Y
Tue Jun 01 00:00:00 UTC 2021
The impact of tobacco exposure on tumor microenvironment and prognosis in lung adenocarcinoma by integrative analysis of multi-omics data.
International immunopharmacology
Lu X,Ma L,Yin X,Ji H,Qian Y,Zhong S,Yan A,Zhang Y
Wed Dec 01 00:00:00 UTC 2021
WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.
Nature communications
Wu M,Xia X,Hu J,Fowlkes NW,Li S
Wed Jun 09 00:00:00 UTC 2021
PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy.
Pathology, research and practice
Paolino G,Pantanowitz L,Barresi V,Pagni F,Munari E,Moretta L,Brunelli M,Bariani E,Vigliar E,Pisapia P,Malapelle U,Troncone G,Girolami I,Eccher A
Fri Oct 01 00:00:00 UTC 2021
Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Journal of nanobiotechnology
Gong C,Yu X,Zhang W,Han L,Wang R,Wang Y,Gao S,Yuan Y
Thu Feb 25 00:00:00 UTC 2021
Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Journal of nanobiotechnology
Gong C,Yu X,Zhang W,Han L,Wang R,Wang Y,Gao S,Yuan Y
Thu Feb 25 00:00:00 UTC 2021
The Mechanism of Mitochondrial Injury in Alpha-1 Antitrypsin Deficiency Mediated Liver Disease.
International journal of molecular sciences
Khodayari N,Wang RL,Oshins R,Lu Y,Millett M,Aranyos AM,Mostofizadeh S,Scindia Y,Flagg TO,Brantly M
Thu Dec 09 00:00:00 UTC 2021
A miR-129-5P/ARID3A Negative Feedback Loop Modulates Diffuse Large B Cell Lymphoma Progression and Immune Evasion Through Regulating the PD-1/PD-L1 Checkpoint.
Frontiers in cell and developmental biology
Zheng W,Lai G,Lin Q,Issah MA,Fu H,Shen J
Wed Nov 17 00:00:00 UTC 2021
Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer.
Cell death discovery
Liu W,Wang Y,Xie Y,Dai T,Fan M,Li C,Zou Y
Sat Jun 05 00:00:00 UTC 2021
OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
Cancer immunology, immunotherapy : CII
Pang X,Wang SS,Zhang M,Jiang J,Fan HY,Wu JS,Wang HF,Liang XH,Tang YL
Thu Apr 01 00:00:00 UTC 2021
OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
Cancer immunology, immunotherapy : CII
Pang X,Wang SS,Zhang M,Jiang J,Fan HY,Wu JS,Wang HF,Liang XH,Tang YL
Thu Apr 01 00:00:00 UTC 2021
Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade.
The Journal of investigative dermatology
Tseng YJ,Lee CH,Chen WY,Yang JL,Tzeng HT
Mon Nov 01 00:00:00 UTC 2021
Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade.
The Journal of investigative dermatology
Tseng YJ,Lee CH,Chen WY,Yang JL,Tzeng HT
Mon Nov 01 00:00:00 UTC 2021
Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade.
The Journal of investigative dermatology
Tseng YJ,Lee CH,Chen WY,Yang JL,Tzeng HT
Mon Nov 01 00:00:00 UTC 2021
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Theranostics
Chen X,Gao A,Zhang F,Yang Z,Wang S,Fang Y,Li J,Wang J,Shi W,Wang L,Zheng Y,Sun Y
Fri Jul 23 00:00:00 UTC 2021
Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug.
Acta biomaterialia
Shen N,Yang C,Zhang X,Tang Z,Chen X
Mon Nov 01 00:00:00 UTC 2021
NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1.
Nature communications
Zhang X,Huang X,Xu J,Li E,Lao M,Tang T,Zhang G,Guo C,Zhang X,Chen W,Yadav DK,Bai X,Liang T
Tue Jul 27 00:00:00 UTC 2021
Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1).
Preparative biochemistry & biotechnology
Wen B,Zhao L,Wang Y,Qiu C,Xu Z,Huang K,Zhu H,Li Z,Li H
Fri Mar 20 00:00:00 UTC 2020
Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1).
Preparative biochemistry & biotechnology
Wen B,Zhao L,Wang Y,Qiu C,Xu Z,Huang K,Zhu H,Li Z,Li H
Fri Mar 20 00:00:00 UTC 2020
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Cancer immunology, immunotherapy : CII
Yan Y,Zheng L,Du Q,Yan B,Geller DA
Tue Sep 01 00:00:00 UTC 2020
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Cancer immunology, immunotherapy : CII
Yan Y,Zheng L,Du Q,Yan B,Geller DA
Tue Sep 01 00:00:00 UTC 2020
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Cancer immunology, immunotherapy : CII
Yan Y,Zheng L,Du Q,Yan B,Geller DA
Tue Sep 01 00:00:00 UTC 2020
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Cancer immunology, immunotherapy : CII
Yan Y,Zheng L,Du Q,Yan B,Geller DA
Tue Sep 01 00:00:00 UTC 2020
α-Cyperone inhibits the proliferation of human cervical cancer HeLa cells via ROS-mediated PI3K/Akt/mTOR signaling pathway.
European journal of pharmacology
Pei XD,Yao HL,Shen LQ,Yang Y,Lu L,Xiao JS,Wang XY,He ZL,Jiang LH
Tue Sep 15 00:00:00 UTC 2020
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.
Cancer cell
Liu H,Kuang X,Zhang Y,Ye Y,Li J,Liang L,Xie Z,Weng L,Guo J,Li H,Ma F,Chen X,Zhao S,Su J,Yang N,Fang F,Xie Y,Tao J,Zhang J,Chen M,Peng C,Sun L,Zhang X,Liu J,Han L,Xu X,Hung MC,Chen X
Mon Mar 16 00:00:00 UTC 2020
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.
Cancer cell
Liu H,Kuang X,Zhang Y,Ye Y,Li J,Liang L,Xie Z,Weng L,Guo J,Li H,Ma F,Chen X,Zhao S,Su J,Yang N,Fang F,Xie Y,Tao J,Zhang J,Chen M,Peng C,Sun L,Zhang X,Liu J,Han L,Xu X,Hung MC,Chen X
Mon Mar 16 00:00:00 UTC 2020
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.
Cancer cell
Liu H,Kuang X,Zhang Y,Ye Y,Li J,Liang L,Xie Z,Weng L,Guo J,Li H,Ma F,Chen X,Zhao S,Su J,Yang N,Fang F,Xie Y,Tao J,Zhang J,Chen M,Peng C,Sun L,Zhang X,Liu J,Han L,Xu X,Hung MC,Chen X
Mon Mar 16 00:00:00 UTC 2020
Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients.
Thoracic cancer
Qin T,Xia J,Liu S,Wang J,Liu H,Zhang Y,Jia Y,Li K
Fri May 01 00:00:00 UTC 2020
Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Cells
Acheampong E,Abed A,Morici M,Bowyer S,Amanuel B,Lin W,Millward M,Gray ES
Sat Oct 31 00:00:00 UTC 2020
LncRNA EMX2OS Induces Proliferation, Invasion and Sphere Formation of Ovarian Cancer Cells via Regulating the miR-654-3p/AKT3/PD-L1 Axis.
Cancer management and research
Duan M,Fang M,Wang C,Wang H,Li M
Mon Jan 29 00:00:00 UTC 2024
NME4 modulates PD-L1 expression via the STAT3 signaling pathway in squamous cell carcinoma.
Biochemical and biophysical research communications
Zheng S,Liu Q,Liu T,Yang L,Zhang Q,Shen T,Zhang X,Han X,Lu X
Thu May 21 00:00:00 UTC 2020
Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma.
Journal of Cancer
Zhu G,Li X,Li J,Zhou W,Chen Z,Fan Y,Jiang Y,Zhao Y,Sun G,Mao W
Fri Oct 16 00:00:00 UTC 2020
Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma.
Journal of Cancer
Zhu G,Li X,Li J,Zhou W,Chen Z,Fan Y,Jiang Y,Zhao Y,Sun G,Mao W
Fri Oct 16 00:00:00 UTC 2020
The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
Cancer immunology, immunotherapy : CII
Komura N,Mabuchi S,Shimura K,Yokoi E,Kozasa K,Kuroda H,Takahashi R,Sasano T,Kawano M,Matsumoto Y,Kodama M,Hashimoto K,Sawada K,Kimura T
Tue Dec 01 00:00:00 UTC 2020
The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
Cancer immunology, immunotherapy : CII
Komura N,Mabuchi S,Shimura K,Yokoi E,Kozasa K,Kuroda H,Takahashi R,Sasano T,Kawano M,Matsumoto Y,Kodama M,Hashimoto K,Sawada K,Kimura T
Tue Dec 01 00:00:00 UTC 2020
Novel gene-specific translation mechanism of dysregulated, chronic inflammation reveals promising, multifaceted COVID-19 therapeutics.
bioRxiv : the preprint server for biology
Wang L,Muneer A,Xie L,Zhang F,Wu B,Mei L,Lenarcic EM,Feng EH,Song J,Xiong Y,Yu X,Wang C,Gheorghe C,Torralba K,Cook JG,Wan YY,Moorman NJ,Song H,Jin J,Chen X
Mon Nov 16 00:00:00 UTC 2020
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.
Cell death & disease
Liu S,Qin T,Liu Z,Wang J,Jia Y,Feng Y,Gao Y,Li K
Mon May 04 00:00:00 UTC 2020
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.
Cell death & disease
Liu S,Qin T,Liu Z,Wang J,Jia Y,Feng Y,Gao Y,Li K
Mon May 04 00:00:00 UTC 2020
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.
Cell death & disease
Liu S,Qin T,Liu Z,Wang J,Jia Y,Feng Y,Gao Y,Li K
Mon May 04 00:00:00 UTC 2020
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.
Cell death & disease
Liu S,Qin T,Liu Z,Wang J,Jia Y,Feng Y,Gao Y,Li K
Mon May 04 00:00:00 UTC 2020
PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis.
Translational lung cancer research
Tuminello S,Sikavi D,Veluswamy R,Gamarra C,Lieberman-Cribbin W,Flores R,Taioli E
Sat Aug 01 00:00:00 UTC 2020
Calcium Channel Blocker Nifedipine Suppresses Colorectal Cancer Progression and Immune Escape by Preventing NFAT2 Nuclear Translocation.
Cell reports
Wu L,Lin W,Liao Q,Wang H,Lin C,Tang L,Lian W,Chen Z,Li K,Xu L,Zhou R,Ding Y,Zhao L
Tue Oct 27 00:00:00 UTC 2020
Mitosis in Cancer Cell Increases Immune Resistance via High Expression of HLA-G and PD-L1.
Cancers
Ullah M,Aoudjeghout W,Pimpie C,Pocard M,Mirshahi M
Fri Sep 18 00:00:00 UTC 2020
Mitosis in Cancer Cell Increases Immune Resistance via High Expression of HLA-G and PD-L1.
Cancers
Ullah M,Aoudjeghout W,Pimpie C,Pocard M,Mirshahi M
Fri Sep 18 00:00:00 UTC 2020
ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer.
Oncoimmunology
Liu Z,Zhao K,Wei S,Liu C,Zhou J,Gou Q,Wu X,Yang Z,Yang Y,Peng Y,Cheng Q,Liu L
Wed May 06 00:00:00 UTC 2020
Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics.
Cell
Li Q,Chen Q,Klauser PC,Li M,Zheng F,Wang N,Li X,Zhang Q,Fu X,Wang Q,Xu Y,Wang L
Thu Jul 09 00:00:00 UTC 2020
Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice.
Oncoimmunology
Qin W,Zou J,Huang Y,Liu C,Kang Y,Han H,Tang Y,Li L,Liu B,Zhao W,Yuan X
Tue Sep 22 00:00:00 UTC 2020
BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes.
OncoTargets and therapy
Li X,Xu Z,Cui G,Yu L,Zhang X
Tue Apr 12 00:00:00 UTC 2022
An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.
Molecular imaging and biology
Wei J,Wang YH,Lee CY,Truillet C,Oh DY,Xu Y,Ruggero D,Flavell RR,VanBrocklin HF,Seo Y,Craik CS,Fong L,Wang CI,Evans MJ
Tue Dec 01 00:00:00 UTC 2020
PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR.
Frontiers in oncology
Lv J,Guo T,Qu X,Che X,Li C,Wang S,Gong J,Wu P,Liu Y,Liu Y,Xu L
Mon Sep 28 00:00:00 UTC 2020
PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR.
Frontiers in oncology
Lv J,Guo T,Qu X,Che X,Li C,Wang S,Gong J,Wu P,Liu Y,Liu Y,Xu L
Mon Sep 28 00:00:00 UTC 2020
Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
Frontiers in oncology
Cai H,Zhang H,Jiang Y
Mon Sep 28 00:00:00 UTC 2020
Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma.
International immunopharmacology
Yang K,Zhou J,Chen Y,Chen Y,Chen L,Zhang P,Ma L,Jiang Z,Bian J,Yin W
Wed Jul 01 00:00:00 UTC 2020
Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma.
International immunopharmacology
Yang K,Zhou J,Chen Y,Chen Y,Chen L,Zhang P,Ma L,Jiang Z,Bian J,Yin W
Wed Jul 01 00:00:00 UTC 2020
Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma.
International immunopharmacology
Yang K,Zhou J,Chen Y,Chen Y,Chen L,Zhang P,Ma L,Jiang Z,Bian J,Yin W
Wed Jul 01 00:00:00 UTC 2020
Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma.
International immunopharmacology
Yang K,Zhou J,Chen Y,Chen Y,Chen L,Zhang P,Ma L,Jiang Z,Bian J,Yin W
Wed Jul 01 00:00:00 UTC 2020
Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma.
International immunopharmacology
Yang K,Zhou J,Chen Y,Chen Y,Chen L,Zhang P,Ma L,Jiang Z,Bian J,Yin W
Wed Jul 01 00:00:00 UTC 2020
Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma.
International immunopharmacology
Yang K,Zhou J,Chen Y,Chen Y,Chen L,Zhang P,Ma L,Jiang Z,Bian J,Yin W
Wed Jul 01 00:00:00 UTC 2020
Ginsenoside Rk1 induces apoptosis and downregulates the expression of PD-L1 by targeting the NF-κB pathway in lung adenocarcinoma.
Food & function
Hu M,Yang J,Qu L,Deng X,Duan Z,Fu R,Liang L,Fan D
Wed Jan 29 00:00:00 UTC 2020
The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer.
American journal of cancer research
Chou CW,Yang RY,Chan LC,Li CF,Sun L,Lee HH,Lee PC,Sher YP,Ying H,Hung MC
Wed Apr 21 00:00:00 UTC 2021
The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer.
American journal of cancer research
Chou CW,Yang RY,Chan LC,Li CF,Sun L,Lee HH,Lee PC,Sher YP,Ying H,Hung MC
Wed Apr 21 00:00:00 UTC 2021
Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
International journal of molecular sciences
Tay WT,Fang YH,Beh ST,Liu YW,Hsu LW,Yen CJ,Liu PY
Tue Mar 31 00:00:00 UTC 2020
Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
International journal of molecular sciences
Tay WT,Fang YH,Beh ST,Liu YW,Hsu LW,Yen CJ,Liu PY
Tue Mar 31 00:00:00 UTC 2020
p.P476S mutation of RBPJL inhibits the efficacy of anti-PD-1 therapy in oesophageal squamous cell carcinoma by blunting T-cell responses.
Clinical & translational immunology
Miao L,Wei XL,Zhao Q,Qi J,Ren C,Wu QN,Wei DL,Liu J,Wang FH,Xu RH
Sun Apr 17 00:00:00 UTC 2022
Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer.
OncoTargets and therapy
Shen LF,Zhou SH,Guo Y
Mon Apr 18 00:00:00 UTC 2022
Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer.
OncoTargets and therapy
Shen LF,Zhou SH,Guo Y
Mon Apr 18 00:00:00 UTC 2022
Synergistic anti-liver cancer effects of curcumin and total ginsenosides.
World journal of gastrointestinal oncology
Deng Z,Xu XY,Yunita F,Zhou Q,Wu YR,Hu YX,Wang ZQ,Tian XF
Thu Oct 15 00:00:00 UTC 2020
Analysis of Cyclooxygenase 2, Programmed Cell Death Ligand 1, and Arginase 1 Expression in Human Pituitary Adenoma.
World neurosurgery
Zhao G,Chen W,He J,Cui C,Zhao L,Zhao Y,Sun C,Nie D,Jin F,Kong L
Tue Dec 01 00:00:00 UTC 2020
Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1.
Genome medicine
Ye Y,Kuang X,Xie Z,Liang L,Zhang Z,Zhang Y,Ma F,Gao Q,Chang R,Lee HH,Zhao S,Su J,Li H,Peng J,Chen H,Yin M,Peng C,Yang N,Wang J,Liu J,Liu H,Han L,Chen X
Mon Sep 28 00:00:00 UTC 2020
Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection.
Antiviral research
Wang T,Chen S,Wang X,Huang Y,Qiu J,Fei Y,Chaulagain A,Chen Y,Wang Y,Lin L,Yan B,Wang Y,Wang W,Zhao W,Zhong Z
Sat Jun 01 00:00:00 UTC 2019
MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Biochimica et biophysica acta. Molecular basis of disease
Xiong W,Deng H,Huang C,Zen C,Jian C,Ye K,Zhong Z,Zhao X,Zhu L
Fri Feb 01 00:00:00 UTC 2019
MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Biochimica et biophysica acta. Molecular basis of disease
Xiong W,Deng H,Huang C,Zen C,Jian C,Ye K,Zhong Z,Zhao X,Zhu L
Fri Feb 01 00:00:00 UTC 2019
MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Biochimica et biophysica acta. Molecular basis of disease
Xiong W,Deng H,Huang C,Zen C,Jian C,Ye K,Zhong Z,Zhao X,Zhu L
Fri Feb 01 00:00:00 UTC 2019
Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma.
Frontiers in oncology
Guo C,Zhao H,Wang Y,Bai S,Yang Z,Wei F,Ren X
Wed Sep 30 00:00:00 UTC 2020
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
Amoils M,Kim J,Lee C,Sunwoo JB,Colevas AD,Aasi SZ,Hollmig ST,Ma Y,Divi V
Tue Jan 01 00:00:00 UTC 2019
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
Amoils M,Kim J,Lee C,Sunwoo JB,Colevas AD,Aasi SZ,Hollmig ST,Ma Y,Divi V
Tue Jan 01 00:00:00 UTC 2019
FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
Journal of immunology (Baltimore, Md. : 1950)
Li P,Huang T,Zou Q,Liu D,Wang Y,Tan X,Wei Y,Qiu H
Wed May 15 00:00:00 UTC 2019
CDK5 Regulates PD-L1 Expression and Cell Maturation in Dendritic Cells of CRSwNP.
Inflammation
Liu CC,Zhang HL,Zhi LL,Jin P,Zhao L,Li T,Zhou XM,Sun DS,Cheng GH,Xin Q,Shi L,Xia M
Fri Feb 01 00:00:00 UTC 2019
CDK5 Regulates PD-L1 Expression and Cell Maturation in Dendritic Cells of CRSwNP.
Inflammation
Liu CC,Zhang HL,Zhi LL,Jin P,Zhao L,Li T,Zhou XM,Sun DS,Cheng GH,Xin Q,Shi L,Xia M
Fri Feb 01 00:00:00 UTC 2019
CDK5 Regulates PD-L1 Expression and Cell Maturation in Dendritic Cells of CRSwNP.
Inflammation
Liu CC,Zhang HL,Zhi LL,Jin P,Zhao L,Li T,Zhou XM,Sun DS,Cheng GH,Xin Q,Shi L,Xia M
Fri Feb 01 00:00:00 UTC 2019
CDK5 Regulates PD-L1 Expression and Cell Maturation in Dendritic Cells of CRSwNP.
Inflammation
Liu CC,Zhang HL,Zhi LL,Jin P,Zhao L,Li T,Zhou XM,Sun DS,Cheng GH,Xin Q,Shi L,Xia M
Fri Feb 01 00:00:00 UTC 2019
PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival.
Frontiers in oncology
Liu S,Qin T,Jia Y,Li K
Wed Sep 30 00:00:00 UTC 2020
EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells.
Biochemical and biophysical research communications
Zhao Y,Wang XX,Wu W,Long H,Huang J,Wang Z,Li T,Tang S,Zhu B,Chen D
Tue Sep 17 00:00:00 UTC 2019
Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma.
Frontiers in oncology
Wang Y,Li JJ,Ba HJ,Wang KF,Wen XZ,Li DD,Zhu XF,Zhang XS
Wed Sep 30 00:00:00 UTC 2020
Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.
Oncology letters
Xu Y,Cui G,Jiang Z,Li N,Zhang X
Fri Mar 01 00:00:00 UTC 2019
Reduced expression of PD-L1 in autoimmune thyroiditis attenuate trophoblast invasion through ERK/MMP pathway.
Reproductive biology and endocrinology : RB&E
Chen M,Gilbert N,Liu H
Sun Oct 27 00:00:00 UTC 2019
Reduced expression of PD-L1 in autoimmune thyroiditis attenuate trophoblast invasion through ERK/MMP pathway.
Reproductive biology and endocrinology : RB&E
Chen M,Gilbert N,Liu H
Sun Oct 27 00:00:00 UTC 2019
Reduced expression of PD-L1 in autoimmune thyroiditis attenuate trophoblast invasion through ERK/MMP pathway.
Reproductive biology and endocrinology : RB&E
Chen M,Gilbert N,Liu H
Sun Oct 27 00:00:00 UTC 2019
Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin.
Frontiers in pharmacology
Zhang S,Zhou L,Zhang M,Wang Y,Wang M,Du J,Gu W,Kui F,Li J,Geng S,Du G
Fri Dec 22 00:00:00 UTC 2023
Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin.
Frontiers in pharmacology
Zhang S,Zhou L,Zhang M,Wang Y,Wang M,Du J,Gu W,Kui F,Li J,Geng S,Du G
Fri Dec 22 00:00:00 UTC 2023
MiR-142 inhibits cecal ligation and puncture (CLP)-induced inflammation via inhibiting PD-L1 expression in macrophages and improves survival in septic mice.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Zhen J,Chen W
Mon Jan 01 00:00:00 UTC 2018
MiR-142 inhibits cecal ligation and puncture (CLP)-induced inflammation via inhibiting PD-L1 expression in macrophages and improves survival in septic mice.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Zhen J,Chen W
Mon Jan 01 00:00:00 UTC 2018
Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma.
Translational oncology
Dai X,Pi G,Yang SL,Chen GG,Liu LP,Dong HH
Sun Apr 01 00:00:00 UTC 2018
Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma.
Translational oncology
Dai X,Pi G,Yang SL,Chen GG,Liu LP,Dong HH
Sun Apr 01 00:00:00 UTC 2018
Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity.
Molecules and cells
Guo J,Qu H,Shan T,Chen Y,Chen Y,Xia J
Tue Jul 31 00:00:00 UTC 2018
Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity.
Molecules and cells
Guo J,Qu H,Shan T,Chen Y,Chen Y,Xia J
Tue Jul 31 00:00:00 UTC 2018
Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy.
Respiratory research
Jin J,Si J,Liu Y,Wang H,Ni R,Wang J
Fri Oct 05 00:00:00 UTC 2018
Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy.
Respiratory research
Jin J,Si J,Liu Y,Wang H,Ni R,Wang J
Fri Oct 05 00:00:00 UTC 2018
A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery.
JAAD case reports
Cannon JGD,Russell JS,Kim J,Chang ALS
Sun Apr 01 00:00:00 UTC 2018
A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery.
JAAD case reports
Cannon JGD,Russell JS,Kim J,Chang ALS
Sun Apr 01 00:00:00 UTC 2018
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.
Nature communications
Hsu JM,Xia W,Hsu YH,Chan LC,Yu WH,Cha JH,Chen CT,Liao HW,Kuo CW,Khoo KH,Hsu JL,Li CW,Lim SO,Chang SS,Chen YC,Ren GX,Hung MC
Tue May 15 00:00:00 UTC 2018
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.
Nature communications
Hsu JM,Xia W,Hsu YH,Chan LC,Yu WH,Cha JH,Chen CT,Liao HW,Kuo CW,Khoo KH,Hsu JL,Li CW,Lim SO,Chang SS,Chen YC,Ren GX,Hung MC
Tue May 15 00:00:00 UTC 2018
Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities.
JAMA dermatology
Chang J,Zhu GA,Cheung C,Li S,Kim J,Chang AL
Sat Apr 01 00:00:00 UTC 2017
Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities.
JAMA dermatology
Chang J,Zhu GA,Cheung C,Li S,Kim J,Chang AL
Sat Apr 01 00:00:00 UTC 2017
Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Clinical and experimental immunology
Jiao Q,Liu C,Li W,Li W,Fang F,Qian Q,Zhang X
Thu Jun 01 00:00:00 UTC 2017
Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Clinical and experimental immunology
Jiao Q,Liu C,Li W,Li W,Fang F,Qian Q,Zhang X
Thu Jun 01 00:00:00 UTC 2017
Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Clinical and experimental immunology
Jiao Q,Liu C,Li W,Li W,Fang F,Qian Q,Zhang X
Thu Jun 01 00:00:00 UTC 2017
Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma.
Translational oncology
Dai X,Xue J,Hu J,Yang SL,Chen GG,Lai PBS,Yu C,Zeng C,Fang X,Pan X,Zhang T
Tue Aug 01 00:00:00 UTC 2017
Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma.
Translational oncology
Dai X,Xue J,Hu J,Yang SL,Chen GG,Lai PBS,Yu C,Zeng C,Fang X,Pan X,Zhang T
Tue Aug 01 00:00:00 UTC 2017
Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment.
Oncotarget
Zhang Y,Sun Z,Mao X,Wu H,Luo F,Wu X,Zhou L,Qin J,Zhao L,Bai C
Tue Oct 17 00:00:00 UTC 2017
Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report.
Medicine
Pi G,He H,Bi J,Li Y,Li Y,Zhang Y,Wang M,Han G,Lin C
Sat Oct 01 00:00:00 UTC 2016
Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report.
Medicine
Pi G,He H,Bi J,Li Y,Li Y,Zhang Y,Wang M,Han G,Lin C
Sat Oct 01 00:00:00 UTC 2016
Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Takada K,Okamoto T,Shoji F,Shimokawa M,Akamine T,Takamori S,Katsura M,Suzuki Y,Fujishita T,Toyokawa G,Morodomi Y,Okano S,Oda Y,Maehara Y
Tue Nov 01 00:00:00 UTC 2016
PD-L1 Expression in Lung Cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Yu H,Boyle TA,Zhou C,Rimm DL,Hirsch FR
Fri Jul 01 00:00:00 UTC 2016
Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
Journal of translational medicine
Song Z,Yu X,Cheng G,Zhang Y
Fri Jun 24 00:00:00 UTC 2016
Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
Journal of translational medicine
Song Z,Yu X,Cheng G,Zhang Y
Fri Jun 24 00:00:00 UTC 2016
Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.
Lung cancer (Amsterdam, Netherlands)
Song Z,Yu X,Zhang Y
Thu Sep 01 00:00:00 UTC 2016
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
Lung cancer (Amsterdam, Netherlands)
Chang YL,Yang CY,Lin MW,Wu CT,Yang PC
Mon Jun 01 00:00:00 UTC 2015
